Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S A for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
By Anthony Fillippleo
Feb 25, 2021
NYC has seen vending machines for engagement rings and Brooks Brothers shirts, as well as PPE like gloves and sanitizing wipes, but this new Manhattan machine is really testing the limits. Since January, a storefront at 225 West 34th Street has hosted two of health company Wellness 4 Humanity’s new vending machines, which sell DIY at-home COVID tests instead of snacks or sodas.
For $149 credit or debit cards only, no cash you can pick up a PCR saliva test, use it at your leisure, mail it to one of the company’s partner labs via FedEx with a pre-printed label and get your results via text or email in 48 hours. Researchers at Memorial Sloan Kettering Cancer Center found that, in the detection of COVID-19, a self-collected saliva sample is as accurate as a nasal swab administered by a health care worker.
BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson s Disease
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 7, 2021 /PRNewswire/ BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced today that the U.S. Food and Drug Administration (FDA) has cleared their Investigational New Drug (IND) application to proceed with a Phase 1 (Ph1) study in patients with advanced Parkinson s disease (PD). This is the first trial in the United States to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson s disease. Under the IND, BlueRock and MSK will execute a Ph1 clinical trial to evaluate the safety, tolerability and preliminary efficacy of DA01 in patients with PD.
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe
December 18, 2020 09:00 ET | Source: Y-mAbs Therapeutics, Inc Y-mAbs Therapeutics, Inc New York, UNITED STATES
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into a distribution agreement with Swixx BioPharma AG (“Swixx”) to be the exclusive distributor of the Company’s antibodies, DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in Eastern Europe, including Russ
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in .
Y-mAbs Therapeutics, IncDecember 18, 2020 GMT
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into a distribution agreement with Swixx BioPharma AG (“Swixx”) to be the exclusive distributor of the Company’s antibodies, DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in Eastern Europe, including Russia. DANYELZA (naxitamab-gqgk) 40mg/10